Citigroup’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$892K Sell
36,024
-15,673
-30% -$373K ﹤0.01% 3192
2025
Q4
$1.21M Buy
51,697
+1,446
+3% +$32.2K ﹤0.01% 3015
2025
Q3
$990K Sell
50,251
-77,509
-61% -$1.59M ﹤0.01% 3169
2025
Q2
$2.77M Sell
127,760
-124,628
-49% -$2.94M ﹤0.01% 2369
2025
Q1
$6.12M Buy
252,388
+32,654
+15% +$735K ﹤0.01% 1729
2024
Q4
$4.59M Buy
219,734
+64,240
+41% +$1.38M ﹤0.01% 2048
2024
Q3
$3.09M Buy
155,494
+40,383
+35% +$749K ﹤0.01% 2283
2024
Q2
$1.78M Sell
115,111
-375,593
-77% -$5.85M ﹤0.01% 2443
2024
Q1
$7.82M Buy
490,704
+284,860
+138% +$4.29M 0.01% 1412
2023
Q4
$3.46M Sell
205,844
-52,482
-20% -$717K ﹤0.01% 1838
2023
Q3
$3.02M Sell
258,326
-28,081
-10% -$376K ﹤0.01% 1722
2023
Q2
$3.85M Sell
286,407
-145,897
-34% -$2.1M ﹤0.01% 1666
2023
Q1
$7.17M Buy
432,304
+143,137
+49% +$2.36M 0.01% 1309
2022
Q4
$5.38M Sell
289,167
-135,470
-32% -$2.09M ﹤0.01% 1440
2022
Q3
$5.45M Buy
424,637
+216,408
+104% +$2.56M ﹤0.01% 1504
2022
Q2
$1.46M Buy
208,229
+149,302
+253% +$1.1M ﹤0.01% 2345
2022
Q1
$489K Sell
58,927
-152,908
-72% -$1.08M ﹤0.01% 3526
2021
Q4
$1.43M Buy
211,835
+79,539
+60% +$523K ﹤0.01% 2902
2021
Q3
$701K Sell
132,296
-162,208
-55% -$887K ﹤0.01% 3370
2021
Q2
$1.69M Sell
294,504
-378,729
-56% -$1.95M ﹤0.01% 2793
2021
Q1
$3.1M Buy
673,233
+652,727
+3,183% +$2.59M ﹤0.01% 2178
2020
Q4
$68K Buy
20,506
+12,796
+166% +$43K ﹤0.01% 5823
2020
Q3
$23K Sell
7,710
-111,168
-94% -$435K ﹤0.01% 6080
2020
Q2
$549K Sell
118,878
-32,951
-22% -$148K ﹤0.01% 4163
2020
Q1
$585K Sell
151,829
-49,301
-25% -$202K ﹤0.01% 3728
2019
Q4
$754K Buy
201,130
+111,656
+125% +$522K ﹤0.01% 4043
2019
Q3
$475K Buy
89,474
+62,542
+232% +$333K ﹤0.01% 4382
2019
Q2
$103K Buy
26,932
+787
+3% +$3.4K ﹤0.01% 5844
2019
Q1
$134K Buy
26,145
+833
+3% +$2.45K ﹤0.01% 5471
2018
Q4
$49K Sell
25,312
-1,165
-4% -$3.33K ﹤0.01% 6262
2018
Q3
$100K Buy
26,477
+4,287
+19% +$13.4K ﹤0.01% 5905
2018
Q2
$69K Sell
22,190
-16,940
-43% -$51.4K ﹤0.01% 6025
2018
Q1
$94K Buy
39,130
+31,928
+443% +$106K ﹤0.01% 5671
2017
Q4
$28K Buy
7,202
+7,067
+5,235% +$23.3K ﹤0.01% 6539
2017
Q3
$0 Sell
135
-45
-25% -$123 ﹤0.01% 7267
2017
Q2
$0 Sell
180
-3,908
-96% -$8.16K ﹤0.01% 7347
2017
Q1
$8K Hold
4,088
﹤0.01% 6628
2016
Q4
$4K Hold
4,088
﹤0.01% 6968
2016
Q3
$4K Sell
4,088
-7,350
-64% -$6.62K ﹤0.01% 6820
2016
Q2
$8K Sell
11,438
-62,174
-84% -$50.1K ﹤0.01% 6623
2016
Q1
$86K Buy
73,612
+50,896
+224% +$79K ﹤0.01% 5761
2015
Q4
$56K Buy
22,716
+22,704
+189,200% +$65K ﹤0.01% 5847
2015
Q3
$0 Sell
12
-967
-99% -$4.17K ﹤0.01% 7416
2015
Q2
$4K Buy
979
+951
+3,396% +$3.79K ﹤0.01% 6849
2015
Q1
$0 Buy
+28
New +$101 ﹤0.01% 7220
2014
Q4
Sell
-10,096
Closed -$34K 7128
2014
Q3
$34K Buy
10,096
+6,558
+185% +$17.1K ﹤0.01% 5553
2014
Q2
$9K Buy
+3,538
New +$7.56K ﹤0.01% 6205
2014
Q1
Sell
-500
Closed -$1K 7033
2013
Q4
$1K Hold
500
﹤0.01% 6848
2013
Q3
$2K Buy
+500
New +$841 ﹤0.01% 6578

Other funds holding CPRX

Citigroup's CPRX Position: Q1 2026 in Review

Citigroup reduced its Catalyst Pharmaceutical (CPRX) stake by 30% in Q1 2026, selling an estimated $373K and leaving 36,024 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #3192.

Citigroup first reported a position in CPRX in Q3 2013 and has held it in 49 quarters since. The position peaked at $7.82M in Q1 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Citigroup held 36,024 shares of Catalyst Pharmaceutical worth $892K as of Q1 2026.
  • Citigroup sold 15,673 Catalyst Pharmaceutical shares in Q1 2026, an estimated $373K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3192 holding.
  • Citigroup first reported a position in Catalyst Pharmaceutical in Q3 2013 and has held it in 49 quarters since.
  • Citigroup's Catalyst Pharmaceutical position peaked at $7.82M in Q1 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.